Experience with intraperitoneal alpha-2a interferon

Ornella Nicoletto, Mario V. Fiorentino, Orazio Vinante, Angelo Prosperi, Flavio Tredese, Salvatore Tumolo, Giovanni P. Cima, Silvio Monfardini

Research output: Contribution to journalArticlepeer-review


Eighteen patients affected with epithelial ovarian cancer have been treated by intraperitoneal α2a-Interferon. The usual single dosage was 54 × 106 U at weekly intervals for four times (eight times in responders): 10 h-istologically confirmed complete remissions and 3 partial remissions have been obtained; the toxicity was represented by fever in the majority of the cases, by abdominal discomfort in some cases, and by a mild transitory neurological complication in 1 case. Seventeen of 18 patients were pretreated, and 11 of 18 had only cytologic and/or microscopic disease. α2a-Interferon has proven to be very effective and moderately toxic in microscopic peritoneal disease of ovarian epithelial cancer previously treated with extensive surgery and intravenous cytotoxic chemotherapy.

Original languageEnglish
Pages (from-to)467-473
Number of pages7
Issue number6
Publication statusPublished - 1992


  • Alpha-2a interferon
  • Intraperitoneal treatment
  • Ovarian epithelial cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Experience with intraperitoneal alpha-2a interferon'. Together they form a unique fingerprint.

Cite this